Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 3Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 127Myeloid 94Sarcoma 69Gastrointestinal 54Lymphoid 28Thoracic 16CNS 15Genitourinary 11Gynecologic 9Dermatologic 9Other solid neoplasm 7Breast 7Tumor-Agnostic 3Plasma cell 3Head & Neck 2Other 1

Conditions

Head and Neck Neoplasms 2Salivary Gland Neoplasms 1Neoplasms, Squamous Cell 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Imatinib Mesylate × Head & Neck × Clear all
NCT00045669 2019-02-15

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

University Health Network, Toronto

Phase 2 Completed
16 enrolled
Head & Neck

Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT00485485 2012-08-07

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
7 enrolled 7 charts
Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡